Pharmacological treatment of cannabis dependence

Keyphrases

• Pharmacological Treatment 100%
• Cannabis Use 100%
• Controlled Experiment 66%
• Cannabis 66%
• Clinical Efficacy 33%
• Psychiatric Conditions 33%
• Drugs of Abuse 33%
• Lithium 33%
• Abstinence 33%
• Endocannabinoids 33%
• Number of Treatment 33%
• Cannabinoid Receptor 1 (CB1R) 33%
• Laboratory Model 33%
• Metabolic Enzymes 33%
• Receptor Antagonist 33%
• Open-label Clinical Trial 33%
• Dysphoric Mood 33%
• Human Laboratory Studies 33%
• Receptor Function 33%
• National Regulatory Authorities 33%
• Treatment Entry 33%
• Fatty Acid Amide Hydrolase Inhibitors 33%
• COMT Inhibitors 33%
• Buspirone 33%
• Methyllycaconitine 33%
• Dronabinol 33%
• URB597 33%
• Entacapone 33%
• Endogenous Cannabinoid 33%
• Cannabis Withdrawal 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cannabis 100%
• Cannabis Addiction 100%
• Controlled Clinical Trial 50%
• Endocannabinoid 50%
• Clinical Trial 25%
• Preclinical Study 25%
• Receptor Antagonist 25%
• Buspirone 25%
• Methyllycaconitine 25%
• Entacapone 25%
• Bungarotoxin Receptor 25%
• Fatty Acid Amidase Inhibitor 25%
• Cannabinoid Receptor 25%
• Catechol Methyltransferase Inhibitor 25%
• URB597 25%
• Dronabinol 25%